D-1456-2019 Class II Ongoing
FDA drug recall D-1456-2019 was initiated by Teva Pharmaceuticals USA on Jun 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing. Affected quantity: 2,943,000 tablets.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 17, 2019
- Initiation Date
- Jun 6, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,943,000 tablets
Product description
LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00
Reason for recall
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Distribution pattern
Nationwide by 4 major distributors.
Code information
Arrow Malta (Teva) Bulk Product Lot # 1163892A, exp. date 01/2020 1163893A, exp. date 01/2020 1163894A, exp. date 01/2020 1163895A, exp. date 01/2020 Golden State Medical Finished Product Lot # GS017042, exp. date 01/2020 GS017043, exp. date 01/2020 GS017044, exp. date 01/2020 GS017541, exp. date 01/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1456-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026